BioCentury
ARTICLE | Clinical News

AZD5213: Phase II started

August 20, 2012 7:00 AM UTC

In its 2Q12 earnings, AstraZeneca said that last quarter it began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 3 doses of once-daily AZD5213 in about 72 patients. ...